Search Results
Your search for this matches 25292 pages
Showing 1151 - 1200ASCO and Google Cloud Announce AI-Powered Tool That Provides Faster, Interactive Access to ASCO’s Evidence-Based Clinical Guidelines
ASCO and Google Cloud have announced a collaboration to launch an artificial intelligence (AI)-based ASCO Guidelines Assistant. Developed with Google Cloud’s Vertex AI platform and Gemini models, the tool is poised to transform how oncology professionals access and use critical clinical...
WGS Liquid Biopsies for HPV-Associated Head and Neck Squamous Cell Carcinoma
Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) detection of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), termed HPV-DeepSeek by the study investigators, showed greater sensitivity, specificity, and diagnostic accuracy than any current...
Revealing Critical Insights for Precision Medicine in Patients With Metastatic Prostate Cancer
Investigators may have uncovered key differences in tumor biology but similarities in survival outcomes in instances of equal access to care between non-Hispanic Black and non-Hispanic White men with metastatic prostate cancer, according to a recent study published by Valle et al in JAMA Network...
Association Between Risk-Reducing Surgeries and Survival in Young BRCA Carriers With Breast Cancer
In an international cohort study reported in The Lancet Oncology, Blondeaux et al evaluated whether both risk-reducing mastectomy and risk-reducing salpingo-oophorectomy were associated with improved survival among women aged 40 or younger who have invasive breast cancer with germline BRCA1/2...
p53 Dysfunction in Myelodysplastic Syndromes
In a study reported in the Journal of Clinical Oncology, Zampini et al identified a proportion of patients with myelodysplastic syndromes who had nonmutational TP53 but p53 dysfunction, which was associated with poor disease outcomes. Study Details The study involved data from a cohort of 6,204...
Breast Cancer: Genome-Wide Study Identifies Two New Risk Genes in Black South African Women
Investigators have identified two genetic risk loci that may be associated with an increased risk of breast cancer for Black South African women, according to findings from a genome-wide association study published in Nature Communications. The two risk loci were between UNC13C and RAB27A on...
Gabapentin May Extend Survival in Patients With Glioblastoma
Investigators have found that the antiseizure/pain drug gabapentin may be associated with improved survival in patients with glioblastoma, according to a recent study published by Bernstock et al in Nature Communications. Background With about 12,000 new cases diagnosed annually in the United...
Stromal Disruption Associated With Higher Risk of Developing Aggressive Breast Cancer
Investigators from the National Cancer Institute (NCI) identified changes in stromal breast tissue, called stromal disruption, that may help to identify women with a higher risk of developing breast cancer, according to study findings published in the Journal of the National Cancer Institute. Women ...
Former President Biden Diagnosed With Metastatic Prostate Cancer
According to his office, Former President Joseph R. Biden Jr has been diagnosed with an “aggressive” type of prostate cancer that has spread to his bones. The New York Times reported that Mr. Biden’s cancer “is characterized by a Gleason score of 9 with metastasis to the bone.” The American Cancer...
Recent Advances in Treating Diffuse Large B-Cell Lymphoma
The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma, and included both lymphomas of B cells and T cells. We now know DLBCL is still heterogenous and some subtypes might benefit...
Antimicrobial Resistance in Outpatients With Cancer
In a U.S. multicenter retrospective cohort study reported in The Lancet Oncology, Gupta et al evaluated whether antimicrobial resistance was more common in pathogenic bacterial isolates from outpatients with cancer than in outpatients without cancer. Study Details The study involved data from the...
Risk of Gynecologic Cancers After 5 Years of Testosterone Use
Transmasculine and gender-diverse patients receiving testosterone as part of their hormone therapy may not be at an increased risk of developing gynecologic cancers in the first years of treatment, according to a recent study published by Vestering et al in eClinicalMedicine. Background Many...
Novel Prediction Model for Hearing Loss From Chemotherapy in Pediatric Patients With Cancer
In a study reported in the Journal of Clinical Oncology, Millstein et al attempted to develop a predictive model—Pediatric Holistic Evaluation of Auditory Risk (PedsHEAR)—for hearing loss associated with cisplatin chemotherapy in children and adolescents with cancer. Study Details PedsHEAR was...
Retifanlimab-dlwr Approved for Anal Cancer
On May 15, the U.S. Food and Drug Administration (FDA) approved retifanlimab-dlwr (Zynyz), a PD-1–blocking monoclonal antibody, with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC)....
Chemotherapy-Free Triplet in Previously Treated HR-Positive, HER2-Positive Advanced Breast Cancer
In a phase IIa study reported in The Lancet Oncology, Escrivá-de-Romani et al evaluated whether the chemotherapy-free triplet of the HER2-targeted bispecific antibody zanidatamab plus palbociclib and fulvestrant showed activity in heavily pretreated patients with hormone receptor (HR)-positive,...
Breast Parenchymal Phenotypes and Risk of Breast Cancer
Six parenchymal phenotypes were established that may be associated with a higher risk of developing breast cancer. Studies of these phenotypes identified by radiomics on mammograms demonstrated that these patterns were associated with an increased risk of invasive breast cancer, according to...
Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in colorectal cancer, offering dynamic insight into disease burden and recurrence risk. However, questions remain about its clinical utility and optimal application, as well as its equitable access across practice settings. At the...
FDA Approves Therapy for NSCLC With High c-Met Protein Overexpression
On May 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis), a c-Met–directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, nonsquamous, non–small cell lung cancer (NSCLC) with high c-Met ...
Case 3: Refractory AML with Complex Karyotype and TP53 Mutation
This is Part 3 of Navigating the Complexities of Relapsed/Refractory AML: Identifying Mutations and Optimizing Targeted Therapy, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Uma Borate, Naval Daver, and Joshua Zeidner...
Case 2: Relapsed/Refractory FLT3-Mutant AML
This is Part 2 of Navigating the Complexities of Relapsed/Refractory AML: Identifying Mutations and Optimizing Targeted Therapy, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Uma Borate, Naval Daver, and Joshua Zeidner...
Case 1: Relapsed KMT2A-Rearranged AML
This is Part 1 of Navigating the Complexities of Relapsed/Refractory AML: Identifying Mutations and Optimizing Targeted Therapy, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Uma Borate, Naval Daver, and Joshua Zeidner...
FDA Approves First Oral Therapy for Pheochromocytoma and Paraganglioma
On May 14, the U.S. Food and Drug Administration approved the oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan (Welireg) for patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA ...
Patient Advocacy Groups: Health-Care Programs Are Lifelines—Not Line Items
Forty nonprofit, nonpartisan organizations issued a statement this week to the House Energy & Commerce and Ways & Means Committees in regard to budget cuts and policy changes affecting Medicaid and health-care marketplaces. “As organizations representing millions of patients with serious...
Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases
In a phase II trial (PEACE V–STORM) reported in The Lancet Oncology, Ost et al found that elective nodal radiotherapy (ENRT) to the pelvis was associated with longer metastasis-free survival vs metastasis-directed therapy (MDT) in patients with pelvic nodal oligorecurrences of prostate cancer....
First-Line TFOX vs FOLFOX in Advanced HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma
In a French phase III trial (PRODIGE 51-FFCD-GASTFOX) reported in The Lancet Oncology, Zaanan et al found that a modified FLOT (fluorouracil, oxaliplatin, and docetaxel) regimen known as TFOX (docetaxel, folinic acid, oxaliplatin, and fluorouracil) improved outcomes vs FOLFOX (folinic acid,...
NCCN Clinical Practice Guidelines in Oncology: 2025 Updates
The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are available for more than 60 tumor types, subtypes, and related topics. During the NCCN’s 30th Annual...
FDA OCE Announces Project Interface Outreach Initiative
The Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA) has launched Project Interface to advance engagement and outreach to patients with cancer, advocacy organizations, and oncology experts. Its mission is to protect, promote, and advance public health by...
AI Model Estimates Biological Age and Predicts Survival in Patients With Cancer
FaceAge, a deep learning system, was developed and validated to estimate biological age from photographs of faces. In a study published in The Lancet Digital Health, FaceAge showed the ability to predict short-term outcomes in patients with cancer. The study demonstrated that FaceAge could...
Revisiting Margin Width Guidelines for Ductal Carcinoma In Situ and the Role of Routine Reexcision
For postmenopausal women with hormone receptor–positive ductal carcinoma in situ (DCIS) treated with breast-conserving surgery, whole-breast irradiation, and adjuvant endocrine therapy, reexcision to achieve wider surgical margins (≥ 1 mm or ≥ 2 mm) may not be necessary, according to data presented ...
Cohort Study Shows Benefits of Bilateral Salpingo-Oophorectomy Without Increased Health Risks
Patients with a history of breast cancer who are carriers of BRCA1 and BRCA2 pathogenic variants benefit from undergoing bilateral salpingo-oophorectomy, the results of a retrospective cohort study published in The Lancet Oncology showed. Women who had their ovaries and fallopian tubes removed...
GLP-1 Receptor Agonists Could Show Anticancer Benefits Beyond Weight Loss
First-generation weight-loss drugs like liraglutide and exenatide could show anticancer benefits beyond weight loss, according to findings from a retrospective, observational study presented by Sagy et al at the European Congress on Obesity (ECO) 2025 and simultaneously published in...
Annual or Biennial Multicancer Early Detection Screening Improves Patient Outcomes
The addition of multi-cancer early detection screening using a single blood sample improved patient outcomes whether conducted on an annual or every 2-year basis, according to findings from a modelling study published in BMJ Open. With earlier detection of disease progression, many cancers could...
In Case You Missed It: Additional Abstracts of Interest From AACR
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...
FDA Approves At-Home Self-Collection Device for Cervical Cancer Screening
Teal Health announced the U.S. Food and Drug Administration’s (FDA) approval of the Teal Wand™, an at-home vaginal sample self-collection device for cervical cancer screening in the United States. The Teal Wand is a prescription device that will soon be available at getteal.com for individuals aged ...
Early-Onset Breast, Colorectal, Endometrial, Pancreatic, and Kidney Cancers on the Rise
Recent studies have shown increasing rates of early-onset cancers, often defined as cancers occurring in people younger than age 50, especially colorectal, pancreatic, female breast, and uterine cancers, and younger birth cohorts seem to have a higher risk of some cancer types compared with older...
FDA Approves Doublet for KRAS-Mutated, Recurrent, Low-Grade Serous Ovarian Cancer
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the combination of the dual RAF/MEK inhibitor avutometinib and the FAK inhibitor defactinib (Avmapki Fakzynja Co-pack) for adults with KRAS-mutated, recurrent, low-grade serous ovarian cancer (LGSOC) who have...
Patterns in Oncology Drug Use After Accelerated Approval Is Withdrawn
The accelerated approval program of the U.S. Food and Drug Administration (FDA) allows certain medications to be marketed if they are indicated for serious disease and there has been preliminary evidence of the drug’s efficacy. Pharmaceutical companies must then conduct postapproval trials to...
Collaborative Strategy Involving AI, Human Task-Sharing Could Help Minimize Mammogram Costs
When screening for breast cancer, the most effective strategy to utilize artificial intelligence (AI) may involve collaboration with human radiologists, according to a recent study published by Ahsen et al in Nature Communications. The findings could help shape how hospitals and clinics integrate...
Breast Cancer Radiotherapy: 1- vs 3-Week Course
A 1-week course of postsurgery radiotherapy demonstrated comparable safety and efficacy to the traditional 3-week regimen in patients with early-stage breast cancer, according to new findings presented by Brunt et al at the European Society for Radiotherapy and Oncology (ESTRO) 2025 Annual Meeting...
How Could So Many Physicians Have Failed Me?
The first sign that something was terribly wrong was in 2015, when I began to feel so fatigued that it was difficult to get out of bed even after 8 to 10 hours of sleep. I’ve been full of energy my whole life and couldn’t understand why I was so tired all the time. Then I began to experience...
Ablative Radiation Therapy for Resectable Pancreatic Ductal Adenocarcinoma
Ablative radiation therapy is considered to be an alternative to surgery, providing an effective noninvasive option for local treatment of many types of cancer, but it is unknown whether ablative radiation therapy is effective for pancreatic ductal adenocarcinoma. Surgery provides improved...
Keith T. Flaherty, MD, FAACR, Elected as AACR President-Elect for 2025–2026
The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, FAACR, as the AACR President-Elect for 2025–2026. He will assume the Presidency in April 2026 at the AACR Annual Meeting in San Diego. Dr. Flaherty is Director of Clinical Cancer Research and the ...
Rakesh K. Jain, PhD, FAACR, Honored With 2025 AACR Award for Lifetime Achievement in Cancer Research
The 2025 AACR Award for Lifetime Achievement in Cancer Research was presented to Rakesh K. Jain, PhD, FAACR, during the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago. This award honors individuals who have made significant fundamental contributions to cancer...
ASH Studies Bolster Support for Menin Inhibitor in Acute Leukemia
The recent approval of the oral menin inhibitor revumenib brought much-needed treatment to patients with a challenging subset of disease: adults and children with relapsed or refractory acute leukemia harboring a lysine methyltransferase 2A gene (KMT2A) translocation or rearrangement. Approval was...
Joint Clinical Practice Guideline Addresses Opioid Conversion for Patients With Cancer
Several medical organizations recently released a joint Clinical Practice Guideline to provide recommendations on opioid conversion in adults with cancer.1 ASCO, together with the Multinational Association of Supportive Care in Cancer (MASCC), American Academy of Hospice and Palliative Medicine,...
2024 Annual Report to the Nation on the Status of Cancer Finds Mortality Rates Continue to Decline
Overall deaths from cancer over the past 2 decades have steadily declined in both men and women in the United States, according to the 2024 Annual Report to the Nation on the Status of Cancer, which was published by Recinda L. Sherman, MPH, PhD, ODS-C, of the North American Association of Central...
Final Overall Survival Data: Amivantamab-vmjw Plus Lazertinib vs Osimertinib in EGFR-Mutated Non–Small Cell Lung Cancer
The phase III MARIPOSA trial was a head-to-head comparison of the EGFR tyrosine kinase inhibitor osimertinib and the combination of the bispecific EGF receptor–directed and MET receptor–directed monoclonal antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib in the first-line ...
Off-the-Shelf Natural Killer CAR T-Cell Therapy Shows Efficacy in Small Study of Relapsed or Refractory Blood Cancers
The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia.1 Over the past decade, other CAR T-cell therapies have been FDA approved to treat adults with blood cancers, including...
Evolving Role of Surgical De-escalation for Endometrial, Ovarian, Cervical, and Vulvar Cancers
For more than a decade, the field of gynecologic oncology has witnessed a movement toward surgical de-escalation through the increased use of minimally invasive surgical techniques and sentinel lymph node techniques. At the 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s...
Study Shows Disparities in Diagnosing Endometrial Cancer in Women With Postmenopausal Bleeding
Angela Nolin, MD, a gynecologic oncology fellow at Duke University Health System in Durham, North Carolina, and colleagues conducted a multi-institutional study to determine whether racial differences in transvaginal ultrasound efficacy combined with timely receipt of indicated endometrial...
